Development and Characterization of Nanoliposomal Hydroxyurea Against BT-474 Breast Cancer Cells

Purpose: Hydroxyurea (HU) is a well-known chemotherapy drug with several side effects which limit its clinical application. This study was conducted to improve its therapeutic efficiency against breast cancer using liposomes as FDA-approved drug carriers. Methods: PEGylated nanoliposomes-containing...

Descripción completa

Detalles Bibliográficos
Autores principales: Akbari, Azam, Akbarzadeh, Azim, Rafiee Tehrani, Morteza, Ahangari Cohan, Reza, Chiani, Mohsen, Mehrabi, Mohammad Reza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tabriz University of Medical Sciences 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6983993/
https://www.ncbi.nlm.nih.gov/pubmed/32002360
http://dx.doi.org/10.15171/apb.2020.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6983993/
https://www.ncbi.nlm.nih.gov/pubmed/32002360
http://dx.doi.org/10.15171/apb.2020.005

Ejemplares similares